Ashoka India Equity Investment Trust

The management team started by explaining that to outperform in India it is all about the management team (since launch the fund has returned -8.70% vs the index which is down -10.01%). In terms of COVID19 it has been very difficult with stringent lockdown measures. The virus is not under control, but it is concentrated in certain areas which means parts of the country are slowly getting back to normal. India will be hit by COVID19, but it has a younger population and much of the support has been targeted at income to vulnerable segments, farmers, daily wage labourers and guaranteed loans to small businesses.

There are structural reforms which could benefit India, for example the labour and competitive federalism reforms could encourage companies to move supply chains from China to India. Also, India will benefit from lower oil prices and on current levels this will save them around $50 billion.

The trust is positioned towards technology where they believe Indian firms are gaining market share and COVID19 has accelerated the change. Financials is another area they like where there are strong balance sheets. They also have healthcare stocks which could benefit from the shift away from China, and some consumer franchises….read more

Fund Facts Morningstar


Please note... is not regulated by the FCA. The information is purely a guide and it is the responsibility of the investor to carry out their own research before making any final decisions. We will ensure that the information is as accurate as possible but we cannot be held accountable for any errors or omissions. No products are sold on this site, nor do we endorse any particular product or investment.

Where there are links to third party sites this is not an endorsement of that site, and we cannot be held responsible for the accuracy of the information on that site.

Where there is reference to performance you should note that past performance is purely a guide and investments can fall as well as rise.

The information on the site belongs to and cannot be replicated or copied without our permission.